721 related articles for article (PubMed ID: 15249677)
1. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.
Liu F; Iqbal K; Grundke-Iqbal I; Hart GW; Gong CX
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10804-9. PubMed ID: 15249677
[TBL] [Abstract][Full Text] [Related]
2. O-GlcNAcylation: A regulator of tau pathology and neurodegeneration.
Gong CX; Liu F; Iqbal K
Alzheimers Dement; 2016 Oct; 12(10):1078-1089. PubMed ID: 27126545
[TBL] [Abstract][Full Text] [Related]
3. Evidence for an imbalance between tau O-GlcNAcylation and phosphorylation in the hippocampus of a mouse model of Alzheimer's disease.
Gatta E; Lefebvre T; Gaetani S; dos Santos M; Marrocco J; Mir AM; Cassano T; Maccari S; Nicoletti F; Mairesse J
Pharmacol Res; 2016 Mar; 105():186-97. PubMed ID: 26816085
[TBL] [Abstract][Full Text] [Related]
4. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.
Liu F; Shi J; Tanimukai H; Gu J; Gu J; Grundke-Iqbal I; Iqbal K; Gong CX
Brain; 2009 Jul; 132(Pt 7):1820-32. PubMed ID: 19451179
[TBL] [Abstract][Full Text] [Related]
5. Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease.
Deng Y; Li B; Liu F; Iqbal K; Grundke-Iqbal I; Brandt R; Gong CX
FASEB J; 2008 Jan; 22(1):138-45. PubMed ID: 17687114
[TBL] [Abstract][Full Text] [Related]
6. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAcylation of protein kinase A catalytic subunits enhances its activity: a mechanism linked to learning and memory deficits in Alzheimer's disease.
Xie S; Jin N; Gu J; Shi J; Sun J; Chu D; Zhang L; Dai CL; Gu JH; Gong CX; Iqbal K; Liu F
Aging Cell; 2016 Jun; 15(3):455-64. PubMed ID: 26840030
[TBL] [Abstract][Full Text] [Related]
8. Prediction of human tau 3D structure, and interplay between O-β-GlcNAc and phosphorylation modifications in Alzheimer's disease: C. elegans as a suitable model to study these interactions in vivo.
Ahmad W; Shabbiri K; Ahmad I
Biochem Biophys Res Commun; 2020 Jul; 528(3):466-472. PubMed ID: 32499112
[TBL] [Abstract][Full Text] [Related]
9. Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting.
Li X; Lu F; Wang JZ; Gong CX
Eur J Neurosci; 2006 Apr; 23(8):2078-86. PubMed ID: 16630055
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease.
Deng Y; Li B; Liu Y; Iqbal K; Grundke-Iqbal I; Gong CX
Am J Pathol; 2009 Nov; 175(5):2089-98. PubMed ID: 19815707
[TBL] [Abstract][Full Text] [Related]
11. O-GlcNAcylation as a Therapeutic Target for Alzheimer's Disease.
Park J; Lai MKP; Arumugam TV; Jo DG
Neuromolecular Med; 2020 Jun; 22(2):171-193. PubMed ID: 31894464
[TBL] [Abstract][Full Text] [Related]
12. O-GlcNAcylation modulates the self-aggregation ability of the fourth microtubule-binding repeat of tau.
Yu CH; Si T; Wu WH; Hu J; Du JT; Zhao YF; Li YM
Biochem Biophys Res Commun; 2008 Oct; 375(1):59-62. PubMed ID: 18671940
[TBL] [Abstract][Full Text] [Related]
13. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
[TBL] [Abstract][Full Text] [Related]
14. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease.
Liu Y; Liu F; Iqbal K; Grundke-Iqbal I; Gong CX
FEBS Lett; 2008 Jan; 582(2):359-64. PubMed ID: 18174027
[TBL] [Abstract][Full Text] [Related]
15. Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease.
Tramutola A; Sharma N; Barone E; Lanzillotta C; Castellani A; Iavarone F; Vincenzoni F; Castagnola M; Butterfield DA; Gaetani S; Cassano T; Perluigi M; Di Domenico F
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3309-3321. PubMed ID: 30031227
[TBL] [Abstract][Full Text] [Related]
16. Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation.
Smet-Nocca C; Broncel M; Wieruszeski JM; Tokarski C; Hanoulle X; Leroy A; Landrieu I; Rolando C; Lippens G; Hackenberger CP
Mol Biosyst; 2011 May; 7(5):1420-9. PubMed ID: 21327254
[TBL] [Abstract][Full Text] [Related]
17. Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies.
Pinho TS; Correia SC; Perry G; Ambrósio AF; Moreira PI
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2048-2059. PubMed ID: 30412792
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.
Yu Y; Zhang L; Li X; Run X; Liang Z; Li Y; Liu Y; Lee MH; Grundke-Iqbal I; Iqbal K; Vocadlo DJ; Liu F; Gong CX
PLoS One; 2012; 7(4):e35277. PubMed ID: 22536363
[TBL] [Abstract][Full Text] [Related]
19. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers.
Yuzwa SA; Cheung AH; Okon M; McIntosh LP; Vocadlo DJ
J Mol Biol; 2014 Apr; 426(8):1736-52. PubMed ID: 24444746
[TBL] [Abstract][Full Text] [Related]
20. Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease.
Liu F; Zaidi T; Iqbal K; Grundke-Iqbal I; Merkle RK; Gong CX
FEBS Lett; 2002 Feb; 512(1-3):101-6. PubMed ID: 11852060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
